国际眼科纵览 ›› 2013, Vol. 37 ›› Issue (3): 200-204.doi: 10 3760/ cma. j. issn.16735803 2013 03 013

• 综述 • 上一篇    下一篇

睑板腺功能障碍的治疗进展

汤韵  晏晓明   

  1. 100034 北京大学第一医院眼科 教育部视觉损伤与修复重点实验室
  • 收稿日期:2013-03-29 出版日期:2013-06-22 发布日期:2013-06-27
  • 通讯作者: 晏晓明,Email:yanxiaoming7908@163.com E-mail:yanxiaoming7908@163.com

The advances in treatments of meibomian gland dysfunction

TANG Yun, YAN Xiao-ming   

  1. Department of Ophthalmology,Peking University First Hospital,  Key Laboratory of Vision Loss and Restoration, Ministry of Education,  Beijing 100034, China
  • Received:2013-03-29 Online:2013-06-22 Published:2013-06-27
  • Contact: YAN Xiao-ming,Email:yanxiaoming7908@163.com E-mail:yanxiaoming7908@163.com

摘要: 睑板腺功能障碍(meibomian gland dysfunction,MGD)在过去几十年中已经逐渐受到临床医师的重视。近年来临床医师使用物理热敷或热装置、人工泪液、局部及全身抗生素、糖皮质激素、环孢素A、调节内分泌、改善生活方式等方法治疗MGD,获得较好的治疗效果,并提出分级治疗的理念。本文旨在介绍近年来MGD治疗理念的变化和治疗方法的进展。

Abstract: The awareness of meibomian gland dysfunction (MGD) has been improved greatly in the past decades. Warm compress/heat application, artificial tears, local/systematic antibiotics, steroids, cyclosporine, sex hormones and improving life style were used as treatments of MGD, improving symptoms and signs. What’s more, practitioners brought up the concept of treatment algorithm based on MGD staging. This article aims to summarize the advances of awareness and treatments on MGD in the past few years.